Halozyme Therapeutics (HALO) Tops Q1 EPS by 10c, Beats on Revenue; Offers Guidance
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $103.00 +4.40%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $0.79, $0.10 better than the analyst estimate of $0.69. Revenue for the quarter came in at $196 million versus the consensus estimate of $199.74 million.
GUIDANCE:
Halozyme Therapeutics sees FY2024 EPS of $3.55-$3.90. Halozyme Therapeutics sees FY2024 revenue of $915-985 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
